What Should Celgene's Investors Do With Everything Bristol-Meyer Squibb Is Giving Them?

With Bristol-Myers Squibb's (NYSE: BMY) acquisition of Celgene (NASDAQ: CELG) expected to close in the third quarter, Celgene's investors have to make a decision: whether to sell now or take $50 in cash plus a share in Bristol-Myers Squibb and a CVR for each share of Celgene they own.